Long-term follow-up of an alemtuzumab (CAMPATH-1H) containing reduced intensity allogeneic transplant regimen for non-Hodgkin's lymphoma (NHL).

被引：0
|
作者：
Morris, E
Thomson, K
Craddock, C
Milligan, D
Smith, GM
Parker, A
Schey, S
Winfield, D
Chopra, R
Littlewood, T
Tighe, J
Hunter, A
Kyriakou, C
Kottaridis, P
Peggs, K
Linch, D
Goldstone, A
Mackinnon, S
机构：
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
139
引用
收藏
页码：40A / 40A
页数：1
相关论文
共 50 条
  • [41] Long-term follow-up in aggressive non-Hodgkin's lymphoma (NHL) patients treated with rHuG-CSF(lenograstim) combined biweekly CHOP chemotherapy.
    Dan, K
    Ogura, M
    Oyama, A
    Asano, S
    BLOOD, 2001, 98 (11) : 344A - 344A
  • [42] Bexxar, iodine I 131 tositumomab, effective in long term follow-up of non-Hodgkin's lymphoma
    Kaminski, Mark
    CANCER BIOLOGY & THERAPY, 2007, 6 (07) : 996 - 997
  • [43] Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma
    L Giaccone
    M Festuccia
    F Zallio
    R Sorasio
    L Brunello
    E Maffini
    C Dellacasa
    R Passera
    G Iovino
    S Aydin
    M Boccadoro
    U Vitolo
    N Mordini
    M Pini
    A Busca
    B Bruno
    Bone Marrow Transplantation, 2017, 52 : 1208 - 1211
  • [44] Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma
    Giaccone, L.
    Festuccia, M.
    Zallio, F.
    Sorasio, R.
    Brunello, L.
    Maffini, E.
    Dellacasa, C.
    Passera, R.
    Iovino, G.
    Aydin, S.
    Boccadoro, M.
    Vitolo, U.
    Mordini, N.
    Pini, M.
    Busca, A.
    Bruno, B.
    BONE MARROW TRANSPLANTATION, 2017, 52 (08) : 1208 - 1211
  • [45] Favorable Long-Term Survival After Reduced-Intensity Allogeneic Transplantation for Multiple-Relapse Aggressive Non-Hodgkin's Lymphoma
    Thomson, Kirsty J.
    Morris, Emma C.
    Bloor, Adrian
    Cook, Gordon
    Milligan, Don
    Parker, Anne
    Clark, Fiona
    Yung, Lynny
    Linch, David C.
    Chakraverty, Ronjon
    Peggs, Karl S.
    Mackinnon, Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (03) : 426 - 432
  • [46] LONG-TERM FOLLOW-UP OF CHOP-TREATED NON-HODGKIN LYMPHOMA OF HIGH-GRADE MALIGNANCY
    HEINZ, R
    BLUT, 1990, 60 (02): : 68 - 75
  • [47] Follow-up (FU) policy after treatment for Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL); The patients view
    Watson, AJ
    Pool, C
    Radford, JA
    BRITISH JOURNAL OF CANCER, 1999, 80 : 20 - 20
  • [48] CHOP compared to THP-COP regimen: Long-term outcome in Chinese non-Hodgkin lymphoma (NHL) patients
    Zhai, L.
    Cheng, C.
    Niraula, S.
    Huang, Y.
    Li, Z. M.
    Wang, S. S.
    Huang, H. Q.
    Lin, T. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [49] A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma
    Khorana, A
    Bunn, P
    McLaughlin, P
    Vose, J
    Stewart, C
    Czuczman, MS
    LEUKEMIA & LYMPHOMA, 2001, 41 (1-2) : 77 - 87
  • [50] Long term follow-up of a phase II study of Rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin's lymphoma (NHL).
    Vose, JM
    Link, BK
    Grossbard, ML
    Czuczman, M
    Grillo-Lopez, A
    Benyunes, M
    Gaynor, E
    Fisher, RI
    BLOOD, 2002, 100 (11) : 361A - 361A
12345